The finder
Pick what you want to change. See who actually measured it.
Every other tool like this gives you a compound and a match score. Those scores are not measured. Ours does not exist. What you get instead is what was actually measured and where: trials in people first with the participant count, then the animal and cell work kept separate, then what people using it report, and the trials that found nothing, counted rather than dropped.
82 of the 444 compounds here have never been through a trial in people. That is worth knowing and it is not a verdict: a molecule nobody can patent has no sponsor to pay for a trial, so a thin human record is usually a fact about money rather than about the compound. Where that is the case, this says so and shows you what does exist.
What are you trying to change?
Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive, so you can see where the evidence is before you choose.
Or start from the compounds
Somebody handed you a stack. What is actually known about it?
Add what you are looking at and you get every outcome those compounds have been measured for in people, and then the longer list of the ones they have not.
Liver fat and liver health
What does it do to the liver?
Fatty liver is the condition the metabolic drugs moved into next, so this is one of the fastest-growing evidence areas here.
8,636 people · 27 human studies · 21 compounds
- 5,169 people1 study
5,169 Chinese participants with measured osteocalcin, plus bidirectional two-sample Mendelian randomisation against Biobank Japan and East Asian diabetes GWAS. Osteocalcin correlated with lower glucose, insulin resistance, triglycerides, liver fat and BMI, but the causal analysis supported type 2 diabetes lowering...
Journal of Bone and Mineral Research, 2021 · 5,169 people
- 1,475 people2 studies
1,075 postmenopausal women randomised to extract with 843 mg EGCG a day or placebo for one year. Adverse events 75.6 versus 72.8 percent; serious 2.2 versus 1.5 percent; more nausea and skin events on extract. ALT elevation in 36 (6.7 percent) versus 4 (0.7 percent), p < 0.001; 1.3 percent had ALT-related serious...
Food and Chemical Toxicology, 2015 · 1,075 people
Secondary analysis of the Minnesota trial (400 women on extract, 98 percent white, mean age 59.8). Mean ALT rose 78 to 82 percent from baseline at months 6 and 9 in UGT1A4 rs6755571 A/C carriers against 28 to 30 percent in C/C, p < 0.001 and p = 0.004. Points to a genetic component in who gets liver injury.
Journal of Dietary Supplements, 2023 · 400 people
- 1,075 people1 study
1,075 postmenopausal women randomised to an extract delivering 843 mg EGCG a day or placebo for one year. Alanine aminotransferase elevation in 36 women on extract (6.7 percent) against 4 on placebo (0.7 percent), p < 0.001, with 1.3 percent having an ALT-related serious adverse event. Overall adverse event rates were...
Food and Chemical Toxicology, 2015 · 1,075 people
- 293 people1 study
48-week trial in 293 adults with biopsy-confirmed MASH: histologic improvement without worsening fibrosis in 47 to 62% on survodutide versus 14% on placebo.
New England Journal of Medicine, 2024 · 293 people
- 181 people1 study1 found nothing
found nothingSYMMETRY, a Phase 2b trial in 181 patients with biopsy-confirmed compensated cirrhosis. The primary endpoint was missed: at 36 weeks fibrosis improved without worsening MASH in 19% on 50 mg against 13% on placebo. At 96 weeks the figures were 29% on 50 mg against 11% on placebo, a 16 percentage point difference (95%...
New England Journal of Medicine, 2025 · 181 people
- 145 people2 studies1 found nothing
found nothing145 participants with liver fat content of 10 percent or more, randomised 1:1 to efinopegdutide 10 mg or semaglutide 1 mg weekly for 24 weeks, open-label. Mean baseline BMI 34.3 and liver fat 20.3 percent; 33.1 percent had type 2 diabetes. Relative reduction in liver fat 72.7 percent (90% CI 66.8 to 78.7) against 42.3...
Journal of Hepatology, 2023 · 145 people
The follow-on programme in steatohepatitis, which is the disease stage where liver fat matters clinically. Liver fat is a biomarker; fibrosis progression and liver outcomes are not.
ClinicalTrials.gov, 2026 · no headcount in the line
- 125 people1 study
125 Chinese adults plus 34 additional Caucasian women without overt type 2 diabetes or cardiovascular disease: plasma MOTS-c was higher, not lower, in those with metabolic syndrome and rose with android and liver fat, the opposite direction from studies in diabetes and coronary disease.
Biochimica et Biophysica Acta, General Subjects, 2021 · 125 people
- 74 people1 study
PROXYMO: 74 people with biopsy-proven non-cirrhotic MASH with fibrosis, randomised to cotadutide 600 mcg, 300 mcg or placebo for 19 weeks. At 600 mcg, absolute liver fat fraction fell 5.0 percentage points against placebo (95 percent CI 1.5 to 8.5), ALT fell 23.5 U per L and AST 16.8 U per L. Any adverse event in...
Clinical Gastroenterology and Hepatology, 2024 · 74 people
- 61 people1 study
61 people with HIV and NAFLD (NCT02196831) randomized to 12 months of tesamorelin 2 mg or placebo, with hepatic fat fraction as the primary endpoint.
The Lancet HIV, 2019 · 61 people
- 20 people1 study1 found nothing
found nothing20 obese adults, mean age 48 and BMI 37, randomised to 1,750 mg a day of TUDCA or placebo for 4 weeks, with two-stage hyperinsulinaemic-euglycaemic clamps, tracer infusions and muscle and adipose biopsies. Hepatic and muscle insulin sensitivity rose approximately 30 percent (p < 0.05) with no change on placebo, and...
Diabetes, 2010 · 20 people
- 17 people3 studies2 found nothing
Eleven healthy obese men, randomised double-blind crossover, 150 mg per day for 30 days. Sleeping and resting metabolic rate fell; muscle AMPK was activated with higher SIRT1 and PGC-1alpha protein and improved mitochondrial respiration on a fatty-acid substrate; intrahepatic lipid, circulating glucose, triglycerides,...
Cell Metabolism, 2011 · 11 people
found nothingThe finding that reframes the null trials. Using 14C-resveratrol in six volunteers, absorption of a 25 mg oral dose was at least 70% and peak plasma resveratrol plus metabolites reached about 2 micromolar with a 9.2 hour half-life, but only trace amounts of unchanged resveratrol were detectable. Rapid intestinal and...
Drug Metabolism and Disposition, 2004 · 6 people
found nothingTwenty overweight or obese men with NAFLD, 3,000 mg daily for eight weeks. No improvement in insulin resistance, steatosis, abdominal fat distribution, plasma lipids or antioxidant activity, and no change in NQO1, PTP1B, IL6 or HO1 transcription. ALT and AST rose significantly versus placebo through week 6, which the...
Clinical Gastroenterology and Hepatology, 2014 · no headcount in the line
- 1 people1 study1 found nothing
found nothingA fully human antibody activating the leptin receptor with or without leptin. In obese leptin knockout mice it normalised body weight, food intake, blood glucose and insulin sensitivity. In a randomised double-blind placebo-controlled two-part phase 1 it was well tolerated. Verbatim: treatment of individuals with...
Science Translational Medicine, 2023 · 1 people
- no headcount stated2 studies
Once-weekly pemvidutide reduced liver fat content in MASLD, with the glucagon component acting directly on the liver.
Journal of Hepatology, 2025 · no headcount in the line
Met MASH resolution without worsening of fibrosis at 24 weeks; did not meet fibrosis improvement at that timepoint.
The Lancet, 2025 · no headcount in the line
- no headcount stated2 studies
ENLIVEN phase 2b, 222 randomised and 219 treated, biopsy-confirmed NASH with F2 or F3 fibrosis, 24 weeks. Fibrosis improvement without NASH worsening: 7 percent placebo, 22 percent on 15 mg weekly, 26 percent on 30 mg weekly (p 0.009), 27 percent on 44 mg every 2 weeks (p 0.008). NASH resolution: 2 percent placebo...
New England Journal of Medicine, 2023 · no headcount in the line
128 randomised at 41 US centres, MASH with F2 or F3 fibrosis, efruxifermin 28 mg or 50 mg weekly or placebo. At 96 weeks, fibrosis improvement of at least one stage without MASH worsening: 19 percent placebo, 30 percent on 28 mg (difference 12 points, p 0.19), 49 percent on 50 mg (difference 31 points, 95 percent CI...
Lancet, 2025 · no headcount in the line
- no headcount stated1 study
Phase 2a substudy (NCT04881760): at 24 weeks, normal liver fat (below 5%) was reached by 86% of participants on 12 mg, 79% on 8 mg and 52% on 4 mg versus 0% on placebo.
Nature Medicine, 2024 · no headcount in the line
- no headcount stated1 study
Oral NR raised blood NAD+ up to 2.7-fold in a human pilot and showed superior hepatic NAD+ kinetics in mice.
Nature Communications, 2016 · no headcount in the line
- no headcount stated1 study
Fibrosis improvement without worsening of MASH at 24 weeks.
New England Journal of Medicine, 2023 · no headcount in the line
- no headcount stated1 study
A multi-part paper. Sulforaphane was identified computationally by matching a type 2 diabetes liver disease signature against 3,800 drug signatures; it suppressed glucose production in hepatic cells via NRF2 nuclear translocation, attenuated glucose intolerance in diabetic animals by a magnitude similar to metformin,...
Science Translational Medicine, 2017 · no headcount in the line
- no headcount stated1 study
The safety report from the same 80-patient trial, 91.3 percent completion, average age 54, 71 percent female. No adverse drug reactions on hepatic, renal or glucose markers and no statistically significant self-reported or major adverse reactions. The stated conclusion is that pterostilbene is generally safe for use...
Journal of Toxicology, 2013 · no headcount in the line
- no headcount stated1 study1 found nothing
found nothingRandomised 2:1, 30 overweight or obese adults aged 45 and over, MIB-626 two 500 mg tablets twice daily for 28 days. Body weight fell 1.9 kg (95 percent CI -3.3 to -0.5, P=.008), diastolic blood pressure fell 7.01 mmHg (-13.44 to -0.59, P=.034), total cholesterol fell 26.89 mg/dL (P=.004) and LDL fell 18.73 mg/dL...
Journal of Clinical Endocrinology and Metabolism, 2023 · no headcount in the line
- no headcount stated1 study
Human plasma measurement in people without diabetes. Both MOTS-c and SHLP2 associated positively with android fat and liver fat. Worth reading carefully: the direction is positive, meaning higher peptide with more fat, which does not sit neatly with the mouse story in which giving the peptide protects against...
Biochimica et Biophysica Acta, General Subjects, 2021 · no headcount in the line
- no headcount stated0 studies
Reduced liver fat and oxidative stress in mice.
JCI Insight, 2025 · no headcount in the line
- no headcount stated0 studies
Fifteen rhesus monkeys with biopsy-confirmed metabolic dysfunction-associated steatohepatitis, given weekly subcutaneous supaglutide at 50 or 150 micrograms per kg or placebo for three months. Liver fat measured by MRI proton density fat fraction fell 40 percent from baseline against placebo, and histological...
Diabetology and Metabolic Syndrome, 2024 · no headcount in the line
- no headcount stated0 studies
The entire mouse lifespan case, from one laboratory. Empagliflozin extended the median survival of male mice by 5.9 percent, improved learning, memory and motor balance, lowered body weight, reduced hepatic P21 and P16, altered gut flora composition and raised short-chain fatty acids. A single-site study, not part of...
GeroScience, 2024 · no headcount in the line
How this is counted
Human studies only. Animal and test-tube work never enters this ranking, because the question you asked was about a person.
A compound is listed for an outcome only when a citation on its own page states that outcome and reports a result for it. Naming it is not enough: a paper that measures testosterone and reports a result about something else does not count as testosterone evidence, which is a mistake this tool made on its first run and no longer makes.
People counts are read out of the study lines themselves and are deliberate undercounts. Where a line states no number, the study still counts as a study and adds nothing to the headcount. Counts are never added across compounds, because the same person can appear in more than one trial.
Ranking is by people measured. That is a fact about the evidence, not a judgement about the compound, and it is the only ordering this site will defend. A compound at the top of a list is the most studied, which is not the same as the best.
Nothing here is advice, and nothing here is a recommendation to take anything.